Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in Hepatocellular Carcinoma
NCT07018947Phase 2Recruiting
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jun 2026
- Primary completion
- Jun 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Fundació Clínic per a la Recerca Biomèdica. Started Jun 2026; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07018947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018947.